Eton Pharmaceuticals Inc (ETON)vsJohnson & Johnson (JNJ)
ETON
Eton Pharmaceuticals Inc
$55.62
+0.47%
HEALTHCARE · Cap: $1.65B
JNJ
Johnson & Johnson
$252.92
-1.21%
HEALTHCARE · Cap: $648.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 92640% more annual revenue ($97.93B vs $105.59M). JNJ leads profitability with a 21.5% profit margin vs 12.0%. JNJ trades at a lower P/E of 31.3x. JNJ earns a higher WallStSmart Score of 59/100 (C).
ETON
Buy52
out of 100
Grade: C-
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ETON.
Margin of Safety
-89.2%
Fair Value
$141.39
Current Price
$252.92
$111.53 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.8%
Revenue surging 98.6% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 33.7x book value
ROE of -4.8% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ETON
The strongest argument for ETON centers on Operating Margin, Revenue Growth. Revenue growth of 98.6% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : ETON
The primary concerns for ETON are Market Cap, P/E Ratio, Price/Book. A P/E of 147.9x leaves little room for execution misses.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ETON profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.90 — expect wider price swings.
ETON is growing revenue faster at 98.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 52/100), backed by strong 21.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?